- Home
- AMTD vs BCAB Comparison
AMTD vs BCAB Comparison
Compare AMTD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTD | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 71.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMTD | BCAB |
|---|---|---|
| Price | $1.10 | $0.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 36.2K | ★ 2.1M |
| Earning Date | 10-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $67,032,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.24 |
| 52 Week High | $1.65 | $1.53 |
Technical Indicators
Market Signals| Indicator | AMTD | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 47.86 |
| Support Level | $1.01 | $0.79 |
| Resistance Level | $1.12 | $0.90 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 77.73 | 23.68 |
Price Performance
Historical ComparisonAbout AMTD AMTD IDEA Group each representing six (6)
AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.